Exosomes are nano-sized vesicles that contain a variety of mRNAs, miRNAs, and proteins. They are capable of being released by a variety of cells and are essential for cell–cell communication. The exosomes produced by cells have shown protective benefits against spinal cord damage (SCI). Recently, it was discovered that M2 macrophages aid in the angiogenesis of numerous illnesses. However, the functional role of M2 macrophage-derived exosomes on SCI is unclear. Here, we investigate the pro-angiogenesis of M2 macrophage-derived exosomes on SCI. We founded that M2 macrophage exosomes alleviated tissue damage and enhanced functional recovery post-SCI. We discovered that M2 macrophage exosome administration increased angiogenesis after SCI in vivo using immunohistochemistry, immunofluorescence labeling, and Western blot analysis. Additionally, the expression of the pro-angiogenesis factors, HIF-1α and VEGF, were enhanced with the treatment of the M2 macrophage exosomes. Furthermore, we found that M2 macrophage exosomes enhanced neurogenesis after SCI in vivo. In vitro, we found that M2 macrophage exosomes can be taken up by the brain endothelial cell line (bEnd.3) and that they enhanced the tube formation, migration, and proliferation of bEnd.3 cells. Furthermore, by using special siRNA to inhibit HIF-1α expression, we observed that the expression of VEGF decreased, and the tube formation, migration, and proliferation of bEnd.3 cells were attenuated with the treatment of HIF-1α-siRNA. In conclusion, our findings reveal that M2 macrophage exosomes improve neurological functional recovery and angiogenesis post-SCI, and this process is partially associated with the activation of the HIF-1/VEGF signaling pathway.
Spinal cord injury (SCI) triggers severe neuroinflammation, impeding recovery. While microglial M1 polarization and pyroptosis are key drivers, their upstream regulators are incompletely understood. This study investigated the role of the ubiquitin ligase tripartite motif‐containing protein 14 (TRIM14) in regulating neuroinflammation following SCI. Using rat SCI models and BV2 microglia exposed to lipopolysaccharide (LPS), we assessed TRIM14 expression and its functional impact via knockdown and overexpression, alongside pharmacological neurofilament (NF)‐κB inhibition (pyrrolidine dithiocarbamate [PDTC]). TRIM14 was upregulated in injured spinal cords and microglia, associated with injury severity. TRIM14 knockdown in microglia stabilized IκBα by inhibiting its ubiquitination, thereby suppressing NF‐κB activation, M1 polarization, and NLRP3‐mediated pyroptosis. Conversely, TRIM14 overexpression exacerbated inflammation, effects markedly reversed by PDTC. In SCI rats, intralesional AAV‐CRISPR/CasRx‐mediated TRIM14 silencing significantly attenuated neuroinflammation and neuronal apoptosis, enhanced axonal regeneration, and improved locomotor function. Mechanistically, TRIM14 knockdown suppressed NF‐κB/NLRP3 signaling, promoting a prorepair microenvironment. These results identify TRIM14 as a critical regulator of microglial activation and pyroptosis post‐SCI, suggesting its therapeutic targeting could be a viable strategy to promote neural repair.